Добавлены профессиональными переводчиками и компаниями и на основе веб-страниц и открытых баз переводов.
erytrocytter fremstillet ved aferese: erytrocytterne fra en erytrocytaferesetapning.
"red cells, apheresis" means the red cells from an apheresis red cell donation.
granulocytter fremstillet ved aferese: en koncentreret granulocytsuspension fremstillet ved aferese.
"granulocytes, apheresis" means a concentrated suspension of granulocytes obtained by apheresis.
generelt bør aferese ikke udføres, hvis trombocyttallet er < 75 x 109/l.
< 100 x 109/l prior to leukapheresis; in general apheresis should not be performed if platelets < 75 x 109/l.
der er ikke sikker klinisk fordel af at reducere den lipidsænkende baggrundsbehandling, herunder aferese.
the clinical benefit of reductions in background lipid-lowering therapy, including apheresis, is not certain.
disse reaktioner kan undgås ved midlertidigt ophør af ace - hæmmerbehandling forud for hver aferese.
these reactions were avoided by temporarily withholding ace-inhibitor therapy prior to each apheresis.
ldl - aferese) hos disse patienter, eller hvis sådanne behandlinger ikke er tilgængelige.
in patients with severe renal insufficiency (creatinine clearance < 30 ml/ min), dosages above 10 mg/ day should be carefully considered and, if deemed necessary, implemented cautiously.
patienter i aferese kan starte behandlingen med 420 mg hver anden uge, så det stemmer overens med deres afereseskema.
patients on apheresis may initiate treatment with 420 mg every two weeks to correspond with their apheresis schedule.
disse reaktioner blev undgået ved en temporær seponering af ace- hæmmer- behandlingen forud for hver aferese.
these reactions were avoided by temporarily withholding ace inhibitor therapy prior to each apheresis.
når plerixafor anvendes til mobilisering af hæmatopoietiske stamceller, kan det medføre mobilisering af leukæmiceller og efterfølgende kontaminering af aferese-produktet.
for the purpose of haematopoietic stem cell mobilisation, plerixafor may cause mobilisation of leukaemic cells and subsequent contamination of the apheresis product.